

Ghrelin and ghrelin/total cholesterol ratio as independent predictors for coronary artery disease: a systematic review and meta-analysis

Maryam Niknam ¹, Taraneh Liaghat,² Mehrdad Zarghami,³ Mehdi Akrami,² Seyed Mehdi Shahnematollahi,² Ahmad Ahmadipour,⁴ Fatemeh Moazzen,⁵ Sahar Soltanabadi ²

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/jim-2021-002100>).

¹Department of Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

²Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

³Cardiology Department, Fasa University of Medical Science, Fasa, Iran

⁴Student Research Committee, Zahedan University of Medical Sciences, Zahedan, Iran

⁵Department of Hematology, Bushehr University of Medical Sciences, Bushehr, Iran

Correspondence to

Dr Sahar Soltanabadi, Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz 7175735865, Iran (the Islamic Republic of); saharsoltany@gmail.com

Accepted 7 December 2021



© American Federation for Medical Research 2022. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Niknam M, Liaghat T, Zarghami M, et al. *J Investig Med* Epub ahead of print: [please include Day Month Year]. doi:10.1136/jim-2021-002100

ABSTRACT

The present meta-analysis aimed to summarize the available data regarding the circulating levels of ghrelin in patients with cardiovascular diseases (CVDs). A comprehensive search was performed in electronic databases including PubMed, Scopus, EMBASE, and Web of Science up to January 20, 2021. Since the circulating levels of ghrelin were measured in different units across the included studies, they were expressed as the standardized mean difference (SMD) and 95% CI (summary effect size). A random-effects model comprising the DerSimonian and Laird method was used to pool SMDs. Sixteen articles (20 studies) comprised of 1087 cases and 437 controls were included. The pooled results showed that there were no significant differences between cases and controls in terms of ghrelin levels (SMD=−0.61, 95% CI −1.38 to 0.16; p=0.120; I²=96.9%, p<0.001). The ghrelin concentrations in the CAD stratum were significantly lower than in controls, whereas they increased in other disease strata. New combined biomarkers demonstrated a significant decrease in the SMD of the ghrelin/total cholesterol (TC) ratio (−1.02; 95% CI −1.74 to −0.29, p=0.000; I²=94.5%). However, no significant differences were found in the SMD of the ghrelin/high-density lipoprotein cholesterol ratio, ghrelin/low-density lipoprotein cholesterol ratio, and ghrelin/triglyceride (TG) ratio in cases with CVDs compared with the control group. Ghrelin was associated with CAD; therefore, it may be considered a biomarker for distinguishing between patients with and without CAD. Furthermore, the ghrelin/TC ratio could be proposed as a diagnostic marker for CVD.

INTRODUCTION

As the leading cause of high rates of morbidity and mortality worldwide, cardiovascular disease (CVD) refers to a combination of linked pathologies which include coronary heart disease (CHD), peripheral arterial disease, cerebrovascular disease, and venous thromboembolism, along with rheumatic and congenital heart diseases. The risk factors for CVD are dyslipidemia, smoking, hypertension, diabetes, and abdominal obesity.^{1–3} As the prevalence of

CVD risk factors rises, the global rate of CVD is expected to increase as well.⁴ The WHO estimates that more than 75% of premature CVD cases are preventable and improving risk factors can help decrease the growing CVD burden.² As a critical chronic condition, obesity has been found to be linked with CVD.⁵ White adipose tissue is a key player in obesity-mediated CVD. It is an active endocrine organ that secretes a variety of adipokines that affect the whole-body homeostasis via different signaling pathways and chemical mediators.⁶ Ghrelin is an important adipokine, which plays a pivotal role in numerous processes in the body.^{7,8} This factor is widely distributed in the heart and is related to cardiovascular risk factors. Ghrelin is implicated in atherosclerosis as the leading cause of coronary artery disease (CAD). Indeed, depending on the atherosclerosis stage, ghrelin has a dual modulatory function in the vascular system.⁹ Thus, the evaluation of this adipokine in patients with CVD appears to be beneficial.^{10–12}

Ghrelin is an adipocyte-derived orexigenic hormone and an endocrine regulatory peptide that serves multiple functions such as increasing appetite and regulating a number of biological cardiovascular processes.^{8,13,14} Non-acylated ghrelin, which is the most abundant form of circulating ghrelin (80%–90%), has been demonstrated to exhibit growth hormone (GH)-releasing capacity. It also has several physiological functions in the cardiovascular system and lipid and glucose metabolism.¹⁵ Moreover, significant associations between the levels of this adipokine and body mass index (BMI), high-density lipoprotein cholesterol (HDL-c) levels, diabetes, and fasting glucose have been reported.¹⁶

Ghrelin is predominantly generated in X/A-type cells of the gastrointestinal tract; however, its production has been observed in other tissues including the myocardium.^{17,18} It has been reported that ghrelin and its receptors exist in the cells of the cardiovascular system, including cardiomyocytes and endothelial cells,^{19–21} and this peptide has been shown to exhibit cardioprotective activities,

such as inhibiting endothelial apoptosis and inflammation, regulating blood pressure, serving as a vasodilator, and increasing the left ventricular function.^{22–24} Thereby, due to its anti-inflammatory effects, and given that it is involved in inhibiting the activation of nuclear transcription factor kappa B (NF- κ B) and the production of inflammatory cytokines in human endothelial cells, ghrelin plays a critical protective function against atherosclerosis and CVDs.^{25 26} The evidence indicates that high levels of ghrelin in plasma could protect healthy individuals against CHD events or deaths.²⁷ Moreover, it was revealed that there is a negative correlation between ghrelin levels and the severity of CAD.^{28 29} These findings confirm the prognostic value of serum ghrelin levels in patients with coronary atherosclerosis and CVDs.

Despite the existence of conventional risk prediction algorithms, the lack of appropriate CVD biomarkers is a critical issue.³⁰ Thus, early detection of risk factors is crucial for disease prevention and morbidity reduction.³¹ There is accumulating evidence that suggests the involvement of ghrelin in cardiovascular function even, although its causative association with CVDs is still debated.⁹ The present systematic review and meta-analysis aimed to summarize the available data regarding the circulating levels of ghrelin with possible atheroprotective functions in patients with CVDs.

METHODS

Search strategy

The meta-analysis was conducted based on the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines.³² The English language studies published until January 20, 2021, were obtained from electronic databases, including PubMed/Medline, Scopus, EMBASE, and Web of Science. The search included the following MeSH (Medical Subject Heading) terms and relevant keywords: (Ghrelin OR “GHRL Protein” OR Ppghrelin OR “Motilin Related Peptide” OR “Motilin-Related Peptide” OR PpMTLRP OR Obestatin OR “Appetite-Regulating Hormone” OR “Appetite Regulating Hormone” OR “Gastric MLTRP”) AND (“Heart Disease” OR “Heart” OR “Coronary Heart Disease” OR “Coronary Artery Disease” OR “CAD” OR “Artery Disease” OR “Coronary Arteriosclerosis” OR “Coronary Atherosclerosis” OR “Atherosclerosis” OR “Ischemia” OR “Myocardial” OR “MI” OR “Myocardial Ischemia” OR “Ischemic Heart Disease” OR “Heart Attack” OR “Heart Disease” OR “Ischemic” OR “Acute Coronary Syndrome” OR “Coronary Syndrome” OR “Acute Coronary” OR “ACS” OR “Angina” OR “Stable Angina” OR “Chronic Stable Angina” OR “Unstable Angina” OR “Coronary Disease” OR “Coronary” OR “Coronary Stenosis” OR “Stenosis” OR “Myocardial Infarction” OR “Infarction” OR “Cardiovascular Stroke” OR “Stroke” OR “Cardiovascular” OR “Myocardial Infarct” OR “Infarct” OR “Non-ST Elevated” “Myocardial Infarction” OR “Non ST Elevated Myocardial Infarction” OR “NSTEMI” OR “Non-ST-Elevation Myocardial Infarction” OR “Non-ST-Elevation Myocardial” OR “Non-ST-Elevation” OR “Non ST Elevation Myocardial Infarction” OR “ST Elevation Myocardial Infarction” OR “ST Segment Elevation Myocardial Infarction” OR “ST Elevated

Myocardial Infarction” OR “STEMI” OR “Atherosclero*” OR “Cardio*” OR “Coronary Occlusion” OR “Stenosis”). In addition, the references of the relevant articles were manually checked for additional desired studies.

Study selection

Original studies of any design, including case-control, cross-sectional, and clinical cohort studies, studies providing detailed information regarding serum or plasma ghrelin levels in patients diagnosed with heart diseases such as CAD, myocardial infarction (MI), CHD, congestive heart failure, atrial fibrillation, heart failure, ischemic heart disease, and hypertensive heart disease and controls (participants without heart diseases and other chronic/metabolic conditions), and studies published in English met the inclusion criteria. Studies using animal models, tissue-based cultures, cell cultures (in vitro or ex vivo), and mRNA expression, as well as case reports, conference abstracts, comments or review articles, editorials, and articles without original data were excluded from the meta-analysis.

Two independent investigators (TL and FM) reviewed the title and the abstract of each article. Following this initial screening step, potential articles were included in our full-text review process. Any existing discrepancies were resolved by consensus or consultation with a third author (MZ).

Data extraction

Three individual authors (MA, AA, and SS) extracted the data using predesigned data collection sheets in Excel. The first author’s name, year of publication, study design, sample size, geographical region, as well as age, BMI, comorbidities, type of heart disease, the levels of triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-c), HDL-c, and ghrelin concentration in patients with CVD and controls (all means \pm SD) were recorded.

Quality assessment

The quality of the study was evaluated using the Newcastle-Ottawa Quality Assessment Scale (NOS), which involved the evaluation of study design and analysis, selection bias, measurements of exposure and outcome, and the generalizability of the results. The NOS tool includes nine items with scores ranging from 0 to 9. Based on the type of study, quality scores ≥ 5 in cross-sectional designs and scores ≥ 7 in case-control or cohort designs represented good quality.

Statistical analysis

All statistical analyses were conducted using STATA V.11.0 (STATA Corp, College Station, Texas, USA). Since the circulation levels of ghrelin were measured in different units across the included studies, they were expressed as the standardized mean difference (SMD) and 95% CI (summary effect size) using Hedges and Olkin SE. Moreover, with regard to the bias-correlation factor in effect size, an exact computation was used. A random-effects model with the DerSimonian and Laird method was used to pool SMDs. χ^2 and inconsistency index (I^2) statistics were also applied to assess inter-study heterogeneity.³³ To explore the source of heterogeneity, subgroup analyses were conducted on the continent where the study was performed and study design,




Figure 1 The flowchart of the study identification and selection process.

as well as the body fluid, type of disease, and other existing medical conditions of the participants. Meta-regression and sensitivity analyses were performed as additional assessments. Funnel plot and Egger's test were also used to examine the potential publication bias in our meta-analysis.

RESULTS

Literature search and study characteristics

The flowchart of the data selection process is shown in [figure 1](#). The primary systematic search led to the retrieval of 1895 records, out of which 1166 were excluded as duplicates and 729 remained as the screened records, resulting in 16 articles (20 studies) as the final records for our meta-analysis.^{16 34–48} The included studies, which were published from 2001 to 2021, were comprised of 1087 cases and 437 controls. Twenty studies reported data on CAD, while the remaining articles investigated other CVDs. Twelve studies were performed in Asia, four in Europe, three in Africa, and one in America. Twelve studies had a case-control design, two were cohort studies, and two had a cross-sectional design. The main characteristics of each included study are summarized in online supplemental table 1.

Pooled effect of ghrelin levels on cases and controls

The pooled results (based on 20 studies) showed that there were no significant differences in ghrelin levels between cases and controls (SMD = -0.61 , 95% CI -1.38 to 0.16 ;

$p=0.120$; $I^2=96.9\%$, $p<0.001$). Forest plots in [figure 2A](#) indicate the pooled SMD and each study on the ghrelin concentrations in cases and controls.

Sensitivity analyses for ghrelin levels showed that after the exclusion of the study by Kilic *et al*,³⁸ the pooled effect was changed (SMD = -0.78 , 95% CI -1.55 to -0.03). In addition, the lower and higher pooled effects for our outcomes, after the one-by-one exclusion of the studies, are shown in [figure 3](#).

Subgroup and meta-regression analyses

In subgroup analyses of ghrelin levels, we found that the levels of ghrelin were decreased in the diabetes/metabolic syndrome (MetS) stratum compared with those without diabetes/MetS comorbidities. The blood concentrations of ghrelin in the CAD stratum were significantly reduced, whereas these concentrations increased in other disease strata. The results of the continent subgroup analysis revealed that ghrelin levels decreased significantly in the Africa and Asia strata but increased in the Europe stratum (online supplemental table 2). Moreover, the findings of univariate meta-regression analyses based on total sample size, publication year, and the quality score showed that none of the moderator variables had a statistically significant effect on ghrelin levels ($p \geq 0.05$).

Combined markers

Regarding new combined markers, the findings revealed a significant decrease in the SMD of the ghrelin/TC ratio




Figure 2 The forest plots of pooled estimates of SMDs of circulating ghrelin, ghrelin/HDL-c, ghrelin/LDL-c, ghrelin/TG, and ghrelin/TC levels between patients with CVDs and controls. CVD, cardiovascular disease; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; SMD, standardized mean difference; TC, triglyceride.

(-1.02; 95% CI -1.74 to -0.29, p=0.000; I²=94.5%). However, no significant differences were found in the SMD of the ghrelin/HDL-c ratio (-0.43; 95% CI -0.96 to 0.10, p=0.000; I²=90.7%), ghrelin/LDL-c ratio (-0.09; 95% CI -0.23 to 0.05, p=0.696; I²=0.000%), and ghrelin/TG ratio (-0.55; 95% CI -1.16 to 0.07, p=0.000; I²=93.1%) in cases with CVDs compared with the control group (figure 2B-E).

Subgroup and meta-regression analyses

In subgroup analyses of ghrelin/TC, ghrelin/HDL-c, and ghrelin/LDL-c levels, there were no significant changes

in different strata, while the heterogeneity of some strata decreased. We found that the levels of ghrelin/TG were significantly decreased in the serum stratum compared with plasma. Moreover, ghrelin/TG blood concentrations in the CAD stratum were significantly reduced, whereas the differences in ghrelin/TG concentrations in other heart disease strata remained non-significant (online supplemental table 2).

To detect the possible source of between-study heterogeneity, a random-effects meta-regression was performed by the mean age and sample size of the intervention group subjects.




Figure 3 The sensitivity analysis results for SMDs of circulating ghrelin levels between patients with CVDs and controls. CVDs, cardiovascular diseases; SMD, standardized mean difference.

We evaluated age as a source of between-study heterogeneity for ghrelin/TC (coef: 0.15, 95% CI=(0.07 to 0.22), $p=0.001$), ghrelin/HDL-c (coef: 0.07, 95% CI=(0.02 to 0.11), $p=0.005$), and ghrelin/TG (coef: 0.39, 95% CI=(0.17 to 0.60), $p=0.002$), but not for ghrelin/LDL-c (coef: 0.00, 95% CI=(-0.00 to 0.01), $p=0.35$). However, we did not find a correlation between the sample size and ghrelin/TC (coef: 0.00, 95% CI=(-0.02 to 0.03), $p=0.88$), ghrelin/HDL-c (coef: 0.00, 95% CI=(-0.01 to 0.16), $p=0.93$), ghrelin/LDL-c (coef: 0.00, 95% CI=(-0.00 to 0.00), $p=0.32$), and ghrelin/TG (coef: 0.00, 95% CI=(-0.07 to 0.07), $p=0.99$).

Publication bias

Visual-filled funnel plots and Egger's test were used to evaluate the potential publication bias across the included studies (online supplemental figure a). However, Egger's tests indicated no significant evidence of publication bias for ghrelin levels (coef=-2.43, $p=0.387$).

DISCUSSION

The incidence of CVDs, as the main cause of death globally, is on the rise as the prevalence of risk factors for these diseases, such as diabetes, hypertension, smoking, dyslipidemia, and abdominal obesity is increasing in previously low-risk countries. Based on previous studies, the effects of these factors are higher in individuals with a genetic predisposition to CVDs.^{1,2,49} Therefore, early diagnosis and treatment of CVDs is a critical issue.^{3,6} Adipose tissue is known as an active endocrine and paracrine organ that secretes several bioactive mediators, including vaspin, chemerin, omentin-1, apelin, and ghrelin.^{6,50} Thus, the dysregulation of these pro-inflammatory and anti-inflammatory adipokines in obesity might account for the link between obesity, insulin resistance (IR), and CVD.⁵¹ The findings obtained from the present meta-analyses revealed that ghrelin levels were not significantly different between the two groups. Moreover, ghrelin levels were lower in patients with CVDs

and diabetes/MetS. In addition, the blood concentrations of ghrelin in the CAD stratum were significantly reduced, whereas these concentrations increased in other disease strata. The results of the continent subgroup analysis revealed that ghrelin levels decreased significantly in the Africa and Asia strata but increased in the Europe stratum. In subgroup analyses of combined biomarkers, we found that the levels of ghrelin/TG were significantly decreased in the serum and CAD strata. Furthermore, meta-regression analyses revealed age as a source of between-study heterogeneity for ghrelin/TC, ghrelin/HDL-c, and ghrelin/TG.

As a gastrointestinal endocrine and cardioactive peptide, ghrelin is generated by cardiomyocytes and has diverse cardioprotective effects, including the inhibition of cardiomyocytes and endothelial cell apoptosis. It improves left ventricular function in ischemia/reperfusion.^{11,52} According to the results of the present study, there was no statistically significant difference between patients with CVD and controls in terms of blood concentrations of ghrelin. Subgroup analyses based on diabetes/MetS comorbidities demonstrated that ghrelin levels were significantly lower in CVD patients with diabetes and MetS than controls. Ghrelin is known to modulate insulin secretion and is considered a promising molecular marker for IR. It was found that ghrelin contributes to the expression of the α -subunits and β -subunits of the insulin receptor. On the other hand, insulin inhibits basal and noradrenaline-triggered ghrelin secretion but does not affect ghrelin mRNA expression.⁵³ It has been reported that a lower ghrelin level is associated with higher severity of MetS indications including obesity, high blood pressure, and IR.⁵⁴ Although ghrelin levels were significantly lower in the CAD subgroup compared with the controls, there were significantly higher levels of ghrelin in patients with other CVDs than in controls. Since CADs are one of the main causes of death worldwide and lead to physical, mental, and social complications,⁵⁵ this adipocytokine may be considered a biomarker for distinguishing between patients with and without CAD. Ghrelin subgroup analyses also showed significantly lower ghrelin levels in Asian and African patients with CVD compared with controls. As shown in previous studies, the dynamics of ghrelin vary due to racial differences, which explains why ghrelin levels differed among subjects from various continents.⁵⁶ The findings on new combined markers indicated a significant decrease in the SMD of the ghrelin/TC ratio; however, no significant differences were observed in the SMD of the ghrelin/HDL-c ratio, ghrelin/LDL-c ratio, and ghrelin/TG ratio in cases with CVDs compared with controls. It has been demonstrated that both acylated ghrelin (AG) and unacylated ghrelin (UAG) bind to lipoproteins through different patterns of binding; AG binds to all lipoproteins and UAG binds more particularly to HDL-c. The binding of ghrelin to lipoproteins may modulate many of its cardiovascular functions. Any changes in the concentration of circulating lipoproteins may therefore impact the concentration of the free hormone available for receptor binding. Given the different patterns of lipoprotein binding, analysis of AG and UAG via separate immunoassays would be more informative.⁵⁷ Subgroup analyses of combined biomarkers revealed that the levels of ghrelin/TG were significantly decreased in the serum and CAD strata. More studies are required to evaluate the ghrelin/TG ratio in the serum of

patients with CVD. Moreover, the ghrelin/TG ratio could be considered a biomarker for patients with CAD, but due to high heterogeneity, further studies are needed to confirm this finding.

The strengths and limitations of this meta-analysis should be taken into consideration. This is the first comprehensive meta-analysis addressing adipocytokine ghrelin in relation to CVD. Subgroup analyses shed some light on the possible sources of heterogeneity in our study. Our meta-analysis has several limitations as well. Given that the studies included in this meta-analysis are heterogeneous, the results of this study should be interpreted with caution. In addition, the observed discrepancies in the present study could be attributed to gender variations, the use of laboratory kits with different characteristics, various atherosclerotic index evaluation methods, or the small sample size of the studies. Therefore, further large-scale studies are required to confirm the results.

CONCLUSION

The results of the current meta-analysis showed that there were no statistically significant differences between patients with CVD and the controls in terms of the blood concentrations of ghrelin. However, ghrelin levels were affected by the region and disease subtypes. Since ghrelin levels were significantly lower in the CAD subgroup compared with the controls, these levels may be considered a biomarker for distinguishing between patients with and without CAD. Based on these findings and as shown in a recent study, ghrelin can be proposed as a predictive biomarker for CVDs.⁵⁸ However, to bring ghrelin into clinical practice, it should exhibit further advantages in predicting cardiovascular risk. Moreover, additional studies are needed to prove that ghrelin indicates an independent relationship with cardiovascular pathology. It is worth mentioning that in addition to the genetic variants of the ghrelin gene, other factors, such as smoking, diet, percutaneous coronary intervention, or medication may affect ghrelin plasma levels. Hence, further research is required to find the risk factors affecting the levels of ghrelin in order to validate the current conclusions and to verify the biological significance of AG and UAG in health status.

Contributors All authors contributed to the study conception. TL, FM, and MZ did the literature search and screening. MA, AA, and SS data extraction. MN, SMS, and SS did the data synthesis, created the tables and figures, and wrote the manuscript. All authors contributed to the interpretation of the data and revision of the manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval This study does not involve human participants.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages),

and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

ORCID iDs

Maryam Niknam <http://orcid.org/0000-0001-7611-7799>

Sahar Soltanabadi <http://orcid.org/0000-0002-3628-9438>

REFERENCES

- 1 Akbari H, Asadikaram G, Jafari A, *et al.* Atorvastatin, losartan and captopril may upregulate IL-22 in hypertension and coronary artery disease; the role of gene polymorphism. *Life Sci* 2018;207:525–31.
- 2 Akbari H, Asadikaram G, Vakili S, *et al.* Atorvastatin and losartan may upregulate reninase activity in hypertension but not coronary artery diseases: the role of gene polymorphism. *J Cell Biochem* 2019;120:9159–71.
- 3 Stewart J, Manmathan G, Wilkinson P. Primary prevention of cardiovascular disease: a review of contemporary guidance and literature. *JRSM Cardiovasc Dis* 2017;6:2048004016687211.
- 4 Perk J, De Backer G, Gohlke H, *et al.* European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). *Eur Heart J* 2012;33:1635–701.
- 5 Cordido F, García-Mayor RV. Obesity, adipose tissue, inflammation and update on obesity management. *Obesity & Control Therapies* 2014;1:1–8.
- 6 Motawi TMK, Mahdy SG, El-Sawalhi MM, *et al.* Serum levels of chemerin, apelin, vaspin, and omentin-1 in obese type 2 diabetic Egyptian patients with coronary artery stenosis. *Can J Physiol Pharmacol* 2018;96:38–44.
- 7 Weir RAP, Chong KS, Dalzell JR, *et al.* Plasma apelin concentration is depressed following acute myocardial infarction in man. *Eur J Heart Fail* 2009;11:551–8.
- 8 Yang D, Liu Z, Luo Q. Plasma ghrelin and pro-inflammatory markers in patients with obstructive sleep apnea and stable coronary heart disease. *Med Sci Monit* 2013;19:251.
- 9 Kadoglou NPE, Lampropoulos S, Kapelouzou A, *et al.* Serum levels of apelin and ghrelin in patients with acute coronary syndromes and established coronary artery disease—KOZANI STUDY. *Transl Res* 2010;155:238–46.
- 10 Chandrasekaran B, Dar O, McDonagh T. The role of apelin in cardiovascular function and heart failure. *Eur J Heart Fail* 2008;10:725–32.
- 11 Sax B, Nadasy GL, Turi K, *et al.* Coronary vasoconstrictor effect of ghrelin is not mediated by growth hormone secretagogue receptor 1A type in dogs. *Peptides* 2011;32:362–7.
- 12 Topuz M, Oz F, Akkus O, *et al.* Plasma apelin-12 levels may predict in-hospital major adverse cardiac events in ST-elevation myocardial infarction and the relationship between apelin-12 and the neutrophil/lymphocyte ratio in patients undergoing primary coronary intervention. *Perfusion* 2017;32:206–13.
- 13 Cummings DE, Weigle DS, Frayo RS, *et al.* Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. *N Engl J Med Overseas Ed* 2002;346:1623–30.
- 14 Fooladi S, Akbari H, Abolhassani M, *et al.* Can estradiol and ghrelin play a protective role in epithelial ovarian cancer incidence in postmenopausal women? *Arch Med Res* 2021;52:324–331.
- 15 Tesaro M, Schinzari F, Caramanti M, *et al.* Metabolic and cardiovascular effects of ghrelin. *Int J Pept* 2010;2010. doi:10.1155/2010/864342. [Epub ahead of print: 16 03 2010].
- 16 Hamed EO, Zaky NA, Din AN. Serum levels of adiponectin and ghrelin in patients with acute myocardial infarction. *Life Sci* 2012;9:523–6.
- 17 Iglesias MJ, Piñeiro R, Blanco M, *et al.* Growth hormone releasing peptide (ghrelin) is synthesized and secreted by cardiomyocytes. *Cardiovasc Res* 2004;62:481–8.
- 18 Kojima M, Hosoda H, Date Y, *et al.* Ghrelin is a growth-hormone-releasing acylated peptide from stomach. *Nature* 1999;402:656–60.
- 19 Katugampola SD, Pallikaras Z, Davenport AP. [125I-His(9)]-ghrelin, a novel radioligand for localizing GHS orphan receptors in human and rat tissue: up-regulation of receptors with atherosclerosis. *Br J Pharmacol* 2001;134:143–9.
- 20 Gnanapavan S, Kola B, Bustin SA, *et al.* The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. *J Clin Endocrinol Metab* 2002;87:2988–91.
- 21 Kleinz MJ, Maguire JJ, Skepper JN, *et al.* Functional and immunocytochemical evidence for a role of ghrelin and des-octanoyl ghrelin in the regulation of vascular tone in man. *Cardiovasc Res* 2006;69:227–35.
- 22 Virdis A, Lerman LO, Regoli F, *et al.* Human ghrelin: a gastric hormone with cardiovascular properties. *Curr Pharm Des* 2016;22:52–8.
- 23 Granata R, Settanni F, Biancone L, *et al.* Acylated and unacylated ghrelin promote proliferation and inhibit apoptosis of pancreatic beta-cells and human islets: involvement of 3',5'-cyclic adenosine monophosphate/protein kinase A,

- extracellular signal-regulated kinase 1/2, and phosphatidylinositol 3-kinase/Akt signaling. *Endocrinology* 2007;148:512–29.
- 24 Granata R, Isgaard J, Alloati G, et al. Cardiovascular actions of the ghrelin gene-derived peptides and growth hormone-releasing hormone. *Exp Biol Med* 2011;236:505–14.
 - 25 Kishimoto I, Tokudome T, Hosoda H, et al. Ghrelin and cardiovascular diseases. *J Cardiol* 2012;59:8–13.
 - 26 Li WG, Gavrilu D, Liu X, et al. Ghrelin inhibits proinflammatory responses and nuclear factor-kappaB activation in human endothelial cells. *Circulation* 2004;109:2221–6.
 - 27 Laurila M, Santaniemi M, Kesäniemi YA, et al. High plasma ghrelin protects from coronary heart disease and Leu72Leu polymorphism of ghrelin gene from cancer in healthy adults during the 19 years follow-up study. *Peptides* 2014;61:122–9.
 - 28 Zhang M, W-y F, Yuan F. Plasma ghrelin levels are closely associated with severity and morphology of angiographically-detected coronary atherosclerosis in Chinese patients with diabetes mellitus. *Acta Pharmacologica Sinica* 2012;33:452–8.
 - 29 Yano Y, Toshinai K, Inokuchi T, et al. Plasma des-acyl ghrelin, but not plasma HMW adiponectin, is a useful cardiometabolic marker for predicting atherosclerosis in elderly hypertensive patients. *Atherosclerosis* 2009;204:590–4.
 - 30 Upadhyay RK. Emerging risk biomarkers in cardiovascular diseases and disorders. *J Lipids* 2015;2015:971453.
 - 31 Bamba V. Update on screening, etiology, and treatment of dyslipidemia in children. *J Clin Endocrinol Metab* 2014;99:3093–102.
 - 32 Tam WWS, Tang A, Woo B, et al. Perception of the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement of authors publishing reviews in nursing journals: a cross-sectional online survey. *BMJ Open* 2019;9:e026271.
 - 33 Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002;21:1539–58.
 - 34 Afify MF, Mohamed GB, El-Maboud MA, et al. Serum levels of ghrelin, tumor necrosis factor-alpha and interleukin-6 in infants and children with congenital heart disease. *J Trop Pediatr* 2009;55:388–92.
 - 35 Chen Y, Ji X-wu, Zhang A-yuan, X-w J, A-y Z, et al. Prognostic value of plasma ghrelin in predicting the outcome of patients with chronic heart failure. *Arch Med Res* 2014;45:263–9.
 - 36 Ghazi H, Al-Shammaa NJ. Association of ghrelin levels with insulin resistance in Iraqi patients with myocardial infarction. *International Journal of Pharmaceutical Research* 2019;11:128–32.
 - 37 Kandil ME, Elwan A, Hussein Y, et al. Ghrelin levels in children with congenital heart disease. *J Trop Pediatr* 2009;55:307–12.
 - 38 Kilic N, Dagli N, Aydin S, et al. Saliva/serum ghrelin, obestatin and homocysteine levels in patients with ischaemic heart disease. *Cardiovasc J Afr* 2017;28:159.
 - 39 Lund LH, Williams JJ, Freda P, et al. Ghrelin resistance occurs in severe heart failure and resolves after heart transplantation. *Eur J Heart Fail* 2009;11:789–94.
 - 40 Matsumoto M, Yasuda S, Miyazaki S, et al. Decreased serum ghrelin levels in patients with acute myocardial infarction. *Tohoku J Exp Med* 2013;231:235–42.
 - 41 Nagaya N, Uematsu M, Kojima M, et al. Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. *Circulation* 2001;104:2034–8.
 - 42 Özcan M, Öztürk GZ, Köse M. Akut dekompanse kalp yetersizliği bulunan hastalarda kan ghrelin ve FeKal elastaz düzeyi ile malnütrisyonun değerlendirilmesi. *Türk Kardiyoloji Derneği Arşivi* 2015;43:131–7.
 - 43 Shahrmanian I, Noori NM, Hashemi M, et al. A study of serum levels of leptin, ghrelin and tumour necrosis factor-alpha in child patients with cyanotic and acyanotic, congenital heart disease. *J Pak Med Assoc* 2013;63:1332–7.
 - 44 Xin X, Ren A-J, Zheng X, et al. Disturbance of circulating ghrelin and obestatin in chronic heart failure patients especially in those with cachexia. *Peptides* 2009;30:2281–5.
 - 45 Yılmaz E, Ustundag B, Sen Y, et al. The levels of ghrelin, TNF- α , and IL-6 in children with cyanotic and acyanotic congenital heart disease. *Mediators Inflamm* 2007;2007:1–5.
 - 46 Zabarovskaja S, Freda P, Williams JJ, et al. Acylation of ghrelin is increased in heart failure and decreases post heart transplantation. *Scand Cardiovasc J* 2014;48:343–8.
 - 47 Zhang M, Fang W-yi, Yuan F, et al. Plasma ghrelin levels are closely associated with severity and morphology of angiographically-detected coronary atherosclerosis in Chinese patients with diabetes mellitus. *Acta Pharmacol Sin* 2012;33:452–8.
 - 48 Zhang Q, Huang W-D, Lv X-Y, et al. The association of ghrelin polymorphisms with coronary artery disease and ischemic chronic heart failure in an elderly Chinese population. *Clin Biochem* 2011;44:386–90.
 - 49 Nowzari Z, Masoumi M, Nazari-Robati M, et al. Association of polymorphisms of leptin, leptin receptor and apelin receptor genes with susceptibility to coronary artery disease and hypertension. *Life Sci* 2018;207:166–71.
 - 50 Shah A, Mehta N, Reilly MP. Adipose inflammation, insulin resistance, and cardiovascular disease. *JEN J Parenter Enteral Nutr* 2008;32:638–44.
 - 51 Mattu HS, Randeve HS. Role of adipokines in cardiovascular disease. *J Endocrinol* 2013;216:T17.
 - 52 Gruzdeva O, Uchasova E, Belik E, et al. Lipid, adipokine and ghrelin levels in myocardial infarction patients with insulin resistance. *BMC Cardiovasc Disord* 2014;14:7.
 - 53 Barazzoni R, Zanetti M, Ferreira C, et al. Relationships between desacylated and acylated ghrelin and insulin sensitivity in the metabolic syndrome. *J Clin Endocrinol Metab* 2007;92:3935–40.
 - 54 Srikanthan K, Feyh A, Visweshwar H, et al. Systematic review of metabolic syndrome biomarkers: a panel for early detection, management, and risk stratification in the West Virginian population. *Int J Med Sci* 2016;13:25.
 - 55 Mohammadi M, Doostkani H, Dadkhah B. Survey of knowledge, attitude and practice of Ardabil citizens about risk factors of coronary artery disease, 2001. *J Ardabil Univ Med Sci* 2002;2:42–8.
 - 56 Bacha F, Arslanian SA. Ghrelin and peptide YY in youth: are there race-related differences? *J Clin Endocrinol Metab* 2006;91:3117–22.
 - 57 Holmes E, Davies I, Lowe G, et al. Circulating ghrelin exists in both lipoprotein bound and free forms. *Ann Clin Biochem* 2009;46:514–6.
 - 58 Yano Y, Nakazato M, Toshinai K, et al. Circulating des-acyl ghrelin improves cardiovascular risk prediction in older hypertensive patients. *Am J Hypertens* 2014;27:727–33.